Récidive axillaire après prélèvement du ganglion sentinelle avant chimiothérapie néoadjuvante dans le cancer du sein

Tardieu, Antoine; Mesnard, C.; Margueritte, François; Mollard, J.; Lacorre, Aymeline; Aubard, Y.; Deluche, Élise; Gauthier, Tristan

doi:10.1016/j.gofs.2018.05.002

Cited by 2 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients treated with NCT had the highest rate of negative hormonal receptors, compared to patients of Non-NCT subgroup, with a significant difference (p<0.001). These findings are very close to those reported in the study of Tardieu et al (2018).…”

Section: Monthssupporting

confidence: 91%

Prognostic Factors, Survival and Benefit of Neoadjuvant Chemotherapy in Operable Breast Cancer in Women from Northwest Algeria

Benchiha

Chama

Saddek

et al. 2023

Egyptian Academic Journal of Biological Sciences. C, Physiology

View full text Add to dashboard Cite

Section: Monthssupporting

confidence: 91%

Prognostic Factors, Survival and Benefit of Neoadjuvant Chemotherapy in Operable Breast Cancer in Women from Northwest Algeria

Benchiha

Chama

Saddek

et al. 2023

Egyptian Academic Journal of Biological Sciences. C, Physiology

View full text Add to dashboard Cite

“…Selective sentinel lymph node biopsy (SLNB) is considered a safe technique for axillary lymph node evaluation without the need for other more invasive techniques as, for example, axillary lymph node dissection [1,2]. At present, this type of surgery, in conjunction with breast-conserving surgery as well as neoadjuvant therapy, is the treatment of choice of those women diagnosed with breast cancer in earlier stages with low metastasis suspicions [3,4].…”

Section: Introductionmentioning

confidence: 99%

Preliminary Study on the Effect of an Early Physical Therapy Intervention after Sentinel Lymph Node Biopsy: A Multicenter Non-Randomized Controlled Trial

Muñoz-Fernández

Medrano-Sánchez

Ostos-Díaz

et al. 2021

IJERPH

View full text Add to dashboard Cite

Selective sentinel lymph node biopsy (SLNB) represents a minimally invasive surgery in patients with breast cancer. The purpose of this study was to explore the possible effect of an early physiotherapy intervention for the recovery of the upper limb and the surgical scars after SLNB in comparison with usual care. A total of 40 patients were enrolled in either the control group (n = 20) or the experimental group (n = 20). The intervention group performed an early physiotherapy program based on functional exercises, scar manual therapy, and educational tips. The control group received usual care. Shoulder range of motion (ROM), grip strength, upper limb pain and disability (SPADI), scar recovery (POSAS), myofascial adhesions (MAP-BC), quality of life (EORTCQLA-BR-23) and the presence of axillary web syndrome (AWS) and lymphoedema were assessed at baseline and immediately after intervention. A follow-up period of 6 months was performed for lymphoedema surveillance. Between groups significant differences in favor of the intervention were found for ROM (r = 0.43), grip strength (r = 0.32), SPADI (d = 0.45), POSAS (d = 1.28), MAP-BC (d = 1.82) and EORTCQLQ-BR 23 general function subscale (d = 0.37) (p < 0.05 for all variables). Our results suggest that an early physical therapy program seems to be more effective than usual care in women after SLNB. However, results should be interpreted with caution and future randomized trial with a larger sample size is needed.

show abstract

Récidive axillaire après prélèvement du ganglion sentinelle avant chimiothérapie néoadjuvante dans le cancer du sein

Cited by 2 publications

References 37 publications

Prognostic Factors, Survival and Benefit of Neoadjuvant Chemotherapy in Operable Breast Cancer in Women from Northwest Algeria

Prognostic Factors, Survival and Benefit of Neoadjuvant Chemotherapy in Operable Breast Cancer in Women from Northwest Algeria

Preliminary Study on the Effect of an Early Physical Therapy Intervention after Sentinel Lymph Node Biopsy: A Multicenter Non-Randomized Controlled Trial

Contact Info

Product

Resources

About